Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Circ Heart Fail. 2016 Aug;9(8):10.1161/CIRCHEARTFAILURE.116.003291 e003291. doi: 10.1161/CIRCHEARTFAILURE.116.003291

Figure 2.

Figure 2

Cardiac function was determined using the Langendorff preparation. L798,106 is an EP3 inhibitor. A–B: PGE2 and sulprostone reduced percent LV +DP/DT via EP3, C: EP4 agonist (CAY10598) increased percent LV +dP/dt, D: EP4 agonist (CAY10598) had no effect on cardiac function in EP4-KO hearts. n=4–6/group. Statistical significance: *p<0.05,**p<0.01,***p<0.001